Skip to main content
Premium Trial:

Request an Annual Quote

Bucher Biotec to Distribute Cell Microsystems Single-Cell Sorting Tool in Switzerland

NEW YORK – Cell Microsystems said on Tuesday that it has signed an exclusive agreement with Bucher Biotec to distribute its image-based single-cell CellRaft AIR System in Switzerland.

Through the agreement, life science researchers in Switzerland will have better access to the Research Triangle Park, North Carolina-based Cell Microsystem's CellRaft AIR system instrument, consumables, and support. 

Cell Microsystem's CellRaft AIR System consists of individual "CellRafts" in a "CytoSort" array of microwells. The firm's platform uses real-time on-array image analysis of single-cell workflows.

Distribution of the CellRaft AIR System through Bucher Biotec began in November. 

"The CellRaft AIR System addresses the needs of researchers to visualize their cells, track and trace their growth, and match them to downstream molecular analyses," Marc Bucher, CEO of Bucher Biotec, said in a statement.

Financial details of the agreement were not disclosed.

"Demand for the CellRaft AIR system has been increasing across European markets, particularly in Switzerland," Gary Pace, CEO of Cell Microsystems, said in a statement. "We are pleased to have Bucher Biotec as our exclusive distributor in Switzerland, which allows us to reach new customers abroad and expand our business in a post-COVID world."

The Scan

Call for a Different Tack

Experts weigh the value of recent experiments testing genetically modified pig kidneys using brain-dead individuals, according to Nature News.

Wastewater Warning

The New York Times reports that wastewater surveillance in some parts of the US point to a possible surge.

Can't Get in the Program

Due to the Northern Ireland protocol dispute, the European Union is preventing UK researchers from joining the Horizon Europe research program, the Times of London reports.

Science Paper on Spatial-Controlled Genome Editing

In Science this week: approach to enable a CRISPR-Cas13a-based system to be used as a cancer therapy.